← Browse by Condition
Medical Condition
wet age related macular degeneration
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 3, Phase 3
ClinicalMetric aggregates all active clinical trials for wet age related macular degeneration from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries. Trials are updated daily as new studies open, status changes, and enrollment targets are updated.
- Recruiting trials — currently enrolling participants, with eligibility criteria
- Phase 1–4 studies — from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary for every trial listing
NCT04704921 Phase 2, Phase 3
Recruiting
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
Enrollment
630 pts
Location
United States
Sponsor
AbbVie
NCT05407636 Phase 3
Recruiting
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Enrollment
660 pts
Location
United States, Canad...
Sponsor
AbbVie